ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

What is the Significance of Denovo Donor Specific Antibodies in Recipients of Simultaneous Liver-Kidney Transplants?

S. Parajuli, F. Aziz, J. Blazel, B. Muth, N. Garg, M. Mohamed, J. Rice, J. Mezrich, L. Hidalgo, D. Mandelbrot, G. Im, B. Lee

University of Wisconsin, Madison, WI

Meeting: 2020 American Transplant Congress

Abstract number: C-123

Keywords: Antibodies, Liver transplantation

Session Information

Session Name: Poster Session C: Liver - Kidney Issues in Liver Transplantation

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: There is limited information about the utility of donor-specific HLA antibody (DSA) testing and the role of protocol kidney biopsy for de-novo donor-specific antibodies (dnDSA) among simultaneous liver and kidney (SLK) transplant recipients.

*Methods: We analyzed our SLK recipients transplanted between 01/2005 and 12/2017 who had DSA tested post-transplant. Patients were divided into two groups based on whether they developed dnDSA post-transplant (dnDSA+) or not (dnDSA-). Patients were excluded if DSA was not tested post SLK. Kidney graft rejection ± 60 days of dnDSA and kidney graft survival were the primary endpoints.

*Results: A total of 91 SLK were transplanted during that period, of which 83 fulfilled our selection criteria. Of those, 23 were in dnDSA+ group and 60 in dnDSA-. 36 recipients had pre-transplant DSA, of which 6 developed dnDSA. None of the baseline characteristics were different between the groups. The mean interval from transplant to the detection of dnDSA was 34 ± 41 months. 22 of 23 dnDSA+ patients had DSA against class II HLA and only one had dnDSA against class I. 15 recipients underwent kidney biopsy after detection of dnDSA, of which 6 were clinically indicated due to rise in serum Cr or proteinuria- none of these 6 had rejection. Of the 9 who had clinically stable kidney function but had a protocol biopsy only due to dnDSA, 6 had rejection (2 antibody mediated, 1 cellular, 3 mixed). Of these 9 patients with dnDSA, in 4 DSA was monitored in routine clinic visit, in one per protocol at 3 months post transplant, in 3 due to liver graft dysfunction and in one due to being on suboptimal immunosuppresive medication due to severe infection. 6 patients underwent liver biopsy, of which 4 had cellular rejection. Of these 4 rejections, one was in the protocol kidney biopsy group, 2 in the clinically indicated kidney biopsy group and one patient underwent isolated liver biopsy without kidney biopsy. At last follow up, dnDSA was not associated with death censored graft failure of kidney (Figure 1) or liver.

*Conclusions: In SLK recipients with dnDSA and stable kidney function, we found that 6 of 9 who were biopsied had subclinical kidney rejection. Possibly in part because of the identification of subclinical rejection and early treatment, outcomes were favorable despite the rejections. Although our study was limited by small sample size, it suggests that DSA monitoring and protocol biopsy for dnDSA may be useful in SLK recipients, as has been previously demonstrated for recipients of kidney transplants alone.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Parajuli S, Aziz F, Blazel J, Muth B, Garg N, Mohamed M, Rice J, Mezrich J, Hidalgo L, Mandelbrot D, Im G, Lee B. What is the Significance of Denovo Donor Specific Antibodies in Recipients of Simultaneous Liver-Kidney Transplants? [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/what-is-the-significance-of-denovo-donor-specific-antibodies-in-recipients-of-simultaneous-liver-kidney-transplants/. Accessed May 11, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences